Twist Bioscience Corporation $TWST Shares Acquired by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 190.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,591 shares of the company’s stock after buying an additional 91,546 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned about 0.23% of Twist Bioscience worth $5,136,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares in the last quarter. Bayforest Capital Ltd lifted its holdings in Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock worth $191,000 after purchasing an additional 1,604 shares during the period. Hsbc Holdings PLC acquired a new stake in Twist Bioscience in the first quarter worth about $228,000. Finally, Xponance Inc. grew its position in Twist Bioscience by 22.0% in the 1st quarter. Xponance Inc. now owns 5,953 shares of the company’s stock valued at $234,000 after buying an additional 1,072 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TWST shares. Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Barclays dropped their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Finally, Evercore ISI dropped their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.56.

Twist Bioscience Trading Up 0.2%

Shares of NASDAQ:TWST opened at $34.18 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -23.57 and a beta of 2.38. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The company has a 50 day moving average price of $28.55 and a 200 day moving average price of $32.04.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 3,876 shares of the business’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $124,768.44. Following the sale, the insider owned 98,710 shares in the company, valued at approximately $3,177,474.90. The trade was a 3.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paula Green sold 9,724 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $313,015.56. Following the sale, the senior vice president directly owned 114,678 shares of the company’s stock, valued at $3,691,484.82. This represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,368 shares of company stock worth $2,036,204 over the last three months. Company insiders own 3.01% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.